Apex Healthcare Consulting

is the MD and founder of Apex Healthcare Consulting. After completing his PhD at Southampton and carrying out post-doctoral research at NorthWestern University, Chicago, he joined the industry first in clinical research and later in project management at Glaxo Laboratories. After completing an MBA in 1993, David joined the International Business Analysis team in Glaxo Holdings, where he spent five years carrying out a variety of strategic projects. In this role he was responsible for commercial analysis and evaluation for a number of international therapy teams most notably working on Zantac for over five years. After leaving GlaxoWellcome in 1996 David established Praxis Research and Consulting with two colleagues, as one of the founding directors. The company focused mainly on market research and in 1998 spun off the consultancy arm so forming an independent group – Apex Healthcare Consulting. In the ten years since Apex began the partnership has grown to ten employees and upwards of ten associates.

is a Project Director at Apex Healthcare Consulting. After completing a BSc at Queen’s University Belfast, Diane joined the pharmaceutical industry in 1987. She spent over nine years as a protein biochemist in drug discovery with SmithKline Beecham, leading research projects in a number of different therapy areas. Diane joined the drug development company, Vanguard Medica (now Vernalis), as Project Evaluation Manager in 1997, where she was responsible for the scientific evaluation of in-licensing opportunities. In 1999 she led the technical due diligence team in the merger of Vanguard Medica with Cerebrus. From 2000 onwards, Diane became Director of Business Development at Vernalis, during which time she managed the technical and commercial aspects of licensing and business development activities in EU, USA and Japan. From 2003, Diane has been a Project Director at Apex Healthcare Consulting, working on a range of due diligence and business development projects for both established and start-up companies and for private equity firms.

Tarun Dey is a Senior Business Analyst with extensive experience of the Pharma/Life Sciences/NHS industry (18 years). In this last job he worked for Wyeth Pharmaceuticals and was responsible for tracking and analyses for all the key hospital products (Enbrel, Tygacil, Refacto, Benefix) and transitioned the data/processes to Pfizer when the Wyeth/Pfizer merger took place. Tarun was instrumental in developing systems for the launch of new product Relistor and worked on innovative strategies to leverage the most complete set of data for Enbrel.

Tarun also worked in IMS for 7 years and has a good understanding of datasets that Pharma companies use. Tarun holds a BA degree in Economics from Calcutta University and System Analyst/Computer Programming qualification from the UK.

Joined Apex as a Project Director in November 2010, with over 12 years of experience in pharma/biotech business development and analysis. After completing a DPhil at Oxford University in 1997, Melanie’s became an analyst at Datamonitor Healthcare. There she specialised in forecasting and strategy, ultimately becoming Head of 21st Century Insight, the healthcare strategy analysis team. In 2002, Melanie joined the business development group at Antisoma, where she was responsible for portfolio analysis, business strategy and forecasting. In her six years at Antisoma, Melanie led due diligence teams on many in-licensing opportunities and was instrumental in out-licensing ASA404 to Novartis in 2006. During that time, she also completed her MBA at London Business School, graduating with Distinction in 2005. From 2008 to 2010, Melanie held the position of Director of Business Development at Biotica, a private biotechnology company, where she completed deals with GlaxoSmithKline and Bristol-Myers Squibb and was responsible for portfolio strategy and marketing.